Forecast Period 
Market Size (Base Year) 
Market Size (Forecast Year)
CAGRGlobal Tumor Transcriptomics Market, By Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Sequencing Technologies), Product (Consumables, Instrument, Others), Application (Diagnostics and Disease Profiling, Drug Discovery, Others) – Industry Trends and Forecast to 2029.
Tumor Transcriptomics Market Analysis and Size
According to the World Health Organization (WHO) reports that cancer is the second biggest cause of mortality globally, accounting for almost one in six fatalities. In 2020, cancer-related fatalities will account for close to 10 million deaths worldwide. The rising prevalence of paediatric cancer are also a significant factor anticipated to fuel market expansion. According to a WHO report, every year, 400,000 children between the ages of 0 and 19 are given cancer diagnoses. Additionally, it is projected that the market expansion will be aided by medical professionals using genetics in cancer treatment.
Data Bridge Market Research analyses that the tumor transcriptomics market which was USD 7.15 billion in 2021, would rocket up to USD 15.84 billion by 2029, and is expected to undergo a CAGR of 10.45% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Tumor Transcriptomics Market Scope and Segmentation
|
Report Metric |
Details |
|
Forecast Period |
2022 to 2029 |
|
Base Year |
2021 |
|
Historic Years |
2020 (Customizable to 2014 - 2019) |
|
Quantitative Units |
Revenue in USD Billion, Volumes in Units, Pricing in USD |
|
Segments Covered |
Tumor Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Others), Technology (Microarray, Real-Time Quantitative, Polymerase Chain Reaction (Q-PCR), Sequencing Technologies), Product (Consumables, Instrument, Others), Application (Diagnostics and Disease Profiling, Drug Discovery, Others) |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Agilent Technologies, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), GENERAL ELECTRIC (U.S.), Fluidigm Corporation (U.S.), Illumina, Inc. (U.S.), 10x Genomics (U.S.), PacBio (U.S.), Merck Sharp & Dohme Corp. (U.S.), Promega Corporation (U.S.), QIAGEN (Germany), Thermo Fisher Scientific Inc. (U.S.) |
|
Market Opportunities |
|
Market Definition
Transcriptomics technologies are the techniques used to study an organism's transcriptome, the sum of its RNA transcripts. There are many uses for transcriptomics, most notably in molecular genetics, which involves studying and collecting transcriptomes. The worldwide transcriptomics market may see numerous new product introductions.
Tumor Transcriptomics Market Dynamics
Drivers
- Rising metastasis analysis
Several factors, including the expanding application of spatial genomic interpretation as a melanoma indicative medium, the tumor's advancing rate, and increasing metastasis analysis and investments, the market for tumour transcriptomics is predicted to grow strongly over the forecast period. The fourth genome sequencing span's appearance and emerging professionals' ability to advance the industry are two other factors driving the business expansion.
- Increasing consumers demand
The market for transcriptomics technologies is being supported by ongoing technological advancement, the launch of trustworthy and effective procedures, and rising consumer demand for more dependable and compact solutions.
Opportunities
The demand for tumour transcriptomics is anticipated to increase due to the increasing knowledge among doctors and patients about the advantages of using sequencing techniques and treatments derived from transcriptomics methods to combat cancer.
Restraints/Challenges
On the other hand, the high capital investment, poor regulatory and reimbursement scenario and slow implementation of technology will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the market.
This tumor transcriptomics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the tumor transcriptomics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Tumor Transcriptomics Market
The COVID-19 pandemic has had an influence on the market and on the healthcare systems. A critical source of possible clinical indicators for clinical decision-making has recently emerged from transcriptomic profiling of liquid biopsies, particularly microRNAs (miRNAs). Furthermore, nations have had and continue to experience a substantial strain on their economies and healthcare systems, which has resulted in the closure of research and academic institutions. The sales of reagents and supplies used in transcriptomics analysis have decreased. According to Nanostring Technologies Inc.'s 2020 annual report, the company's Consumables section had a sharp fall of 18% from 2019.
Recent Development
- In March 2020, Agilent Technologies Inc. launched Agilent GenetiSure Cyto microarrays for prenatal and postnatal research.
- In April 2020, An international collaborative alliance to improve customised medication in cancer using IndivuType, the business's multi-omics database, was established by the oncology company Indivumed GmbH.
Global Tumor Transcriptomics Market Scope
The tumor transcriptomics market is segmented on the basis of tumor type, technology, product and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Tumor Type
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Others
Technology
- Microarray
- Real-Time Quantitative
- Polymerase Chain Reaction (Q-PCR)
- Sequencing Technologies
Product
- Consumables
- Instrument
- Others
Application
- Diagnostics
- Disease Profiling
- Drug Discovery
- Others
Tumor Transcriptomics Market Regional Analysis/Insights
The tumor transcriptomics market is analysed and market size insights and trends are provided by country, tumor type, technology, product and application as referenced above.
The countries covered in the tumor transcriptomics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the tumor transcriptomics market due to the great pervasiveness of breast malignancy sufferers.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to attraction of various organized business professionals to augment their occupancy in this singular domain.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Tumor Transcriptomics Market Share Analysis
The tumor transcriptomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to tumor transcriptomics market.
Some of the major players operating in the tumor transcriptomics market are:
- Agilent Technologies, Inc. (U.S.)
- F. Hoffmann-La Roche AG (Switzerland)
- Bio-Rad Laboratories, Inc. (U.S.)
- GENERAL ELECTRIC (U.S.)
- Fluidigm Corporation (U.S.)
- Illumina, Inc. (U.S.)
- 10x Genomics (U.S.)
- PacBio (U.S.)
- Merck Sharp & Dohme Corp. (U.S.)
- Promega Corporation (U.S.)
- QIAGEN (Germany)
- Thermo Fisher Scientific Inc. (U.S.)
SKU-
